Fennec Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Fennec Pharmaceuticals reported 3rd quarter 2026 net product sales of $19.4 million, up approximately 56% year over year from $12.5 million in the 3rd quarter of 2025.
- Commercial demand grew at a double-digit rate compared with the prior quarter; Fennec HEARS patient enrollments increased 23% and completed infusions increased 58% compared with the 2nd quarter of 2026, both reaching records.
- Fennec reported approximately $5.8 million of non-GAAP adjusted EBITDA, or 30% of net product sales, compared with $2 million, or 16%, in the comparable quarter a year ago and $2.8 million, or 16%, in the 2nd quarter.
- The company generated nearly $7 million in cash from operations, reported 3rd quarter EPS of $0.12 per share versus a loss of $0.02 per share a year ago, and had $48.7 million of cash and cash equivalents as of September 30th, 2026, with no debt.
- Fennec reported results from the investigator-initiated Phase 2 trial STS-001 at the SIOP annual meeting, describing significant hearing protection and clinical context regarding antitumor activity with delayed Pedmark administration.
- Fennec secured a formulary win with a large Midwestern academic center and its home infusion service; management said the win had some 3rd quarter use, with more significant activity beginning in the 4th quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Fennec Pharmaceuticals Third Quarter 2026 Earnings and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.
Please go ahead. Thank you, operator, and good morning, everyone.
Thank you for joining us. We are pleased to host Fennec Pharmaceuticals Third Quarter 2026 Earnings Conference Call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. With that, I will now turn the call over to Jeff Hackman.
Thank you, Robert, and good morning, everyone. Thank you for joining us here today. We are pleased to report yet another quarter of revenue growth, reflecting continued progress across our business and the positive momentum that we are building around PEDMARK. As we look ahead, we remain focused on executing our commercial strategy, strengthening the evidence supporting the use of PEDMARK, and expanding opportunities to reach more patients who may benefit from this treatment. Today, I'd like to highlight two significant areas of progress from the quarter. First, we are realizing the benefits of the investments that we made in our Project Ignite, which is a strategic expansion of our sales organization. We did this in the first quarter of the year.
We invested in 14 territories, four frontline managers to expand our ability to engage healthcare professionals, support the adoption of our product, and strengthen our commercial presence across priority markets. We now have two full quarters in the field with our new territory managers, and they are delivering significant product productivity gains. Greater efficiency is enabling us to reach more healthcare professionals and engage them more frequently across our targeted segments. We are seeing strong uptake in the community with oncologists, and we remain focused on accelerating adoption at academic centers. This momentum is strengthening our presence and relationships across these new and existing accounts. We are very encouraged by this continued progress, and we believe that the productivity curve will continue to increase through the fourth quarter and through into 2027.
Commercial demand continued to grow at a double-digit rate in the third quarter compared to the prior quarter, driven primarily through our Fennec HEARS program, which is our patient services hub. Patient enrollments in Fennec HEARS increased 23%, leading to a record number of infusions, up 58% compared to the second quarter of 2026. We also achieved a record AYA enrollment in Fennec HEARS during the third quarter, supported by our NCCN 2A recommendations. As a reminder, PEDMARK is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors and is recognized by the National Comprehensive Cancer Network, or NCCN, with a 2A recommendation for use in AYA patients. As we have discussed, GPOs and their vertically integrated oncology models are an important driver of patient care in the community settings.
This year, we built upon our formulary wins by expanding our partnerships with these community practice aggregators to access tumor-specific data and diagnosis codes for AYA patients. The data has been highly actionable. The third quarter was the first quarter for this internal alert program, which allows us to target new providers with active patients who could be appropriate for PEDMARK. Our team is becoming much more effective every month at engaging these prescribers. Using this data in the third quarter, we successfully added multiple new accounts and expanded utilization within existing ones. We anticipate the growing use of the data to be one of the fundamental drivers of adding new accounts in the community setting going forward. We are also having expanded use of PEDMARK in the academic setting.
Our market access team recently secured another formulary win with a very large Midwestern academic center and their home infusion service. This inclusion enables physicians across the entire center to seamlessly prescribe PEDMARK to patients at risk of CIO. The formulary win removes historical barriers to adoption and opens up the door to potentially hundreds of additional patients in this academic center alone. These types of wins are good examples of how our commercial, medical, and market access teams are working together to remove barriers and expand access across these key institutions. By increasing access in both academic and community practices, we are driving new demand and successfully changing the standard of care with PEDMARK. A second area of progress is our investment in evidence generation, which is beginning to yield important scientific results.
At the most recent SIOP annual meeting, we detailed results from an investigator-initiated phase II trial, STS-J01, evaluating PEDMARK for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent young adults with non-metastatic tumors in Japan, where we were featured in an oral presentation. The data demonstrates significant hearing protection and provides reassurance and clinical context regarding anti-tumor activity with delayed PEDMARK administration. This represents the first public exchange of detailed results from an investigator-initiated study, and we look forward to full results from the trial being published in a peer-reviewed publication in the future. As you recall, we set a strategy in the fourth quarter of 2025 to partner with leading academic institutions to advance independent research and generate new clinical data and expand insights across additional tumor types and patient populations. We are starting to see results of these partnerships.
Some exciting data forthcoming in adult and metastatic patient populations are coming. In early January, City of Hope Cancer Center plans to present interim data from its investigator-initiated study at one of the largest, most influential meetings focused on testicular cancer. The study is evaluating PEDMARK for the prevention of cisplatin-induced ototoxicity, or CIO, in adult men with stage 2 and 3 metastatic testicular germ cell tumors. We believe the interim data will provide an important opportunity to engage clinical communities and advance the discussion around PEDMARK's potential in hearing loss prevention. Additionally, City of Hope will present real-world feasibility and observed toxicity findings for PEDMARK, which utilized a deep dive into collected data from our Fennec HEARS program in adults with germ cell tumors receiving platinum-based chemo.
In summary, we are realizing the benefits of strategic investments and initiatives put into motion at the start of 2026, and we firmly believe PEDMARK has the potential to deliver continued sustainable growth. We are working to realize the potential through disciplined commercial execution, a growing body of evidence to support its use, and ongoing operational enhancements, and designed to improve overall experience for our patients and healthcare professionals. We are confident today in the opportunity ahead and focused on turning today's progress into long-term value for our patients, our healthcare professionals, and our shareholders. With that, I am going to turn the call back over to Robert for a financial update.
Thank you, Jeff. Our press release contains details of our financial results for the third quarter of 2026, which can be viewed on the Investors and Media section of our website, www.fennecpharma.com. My comments today will focus on highlighting some key financial results. Let me start by stating that Fennec just reported the best commercial quarter in its history. Entering the fourth quarter of 2026, we have the largest number of patients, planned infusions, and planned vials being carried over from the third quarter. Importantly, we have strong visibility into the strength of our fourth quarter as a result of the third quarter carryover and after a strong October. For the third quarter of 2026, the company recorded net product sales of $19.4 million compared to $12.5 million in the third quarter of 2025, representing an increase of approximately 56% year over year.
We continued to build on our second quarter performance by expanding PEDMARK use with both new and existing customers and the increasing productivity from our commercial team. On the OPEX side, which we define as R&D and SG&A, excluding stock-based compensation, it was approximately $12.7 million for the quarter, with a year-over-year increase of about $3 million. The majority of the increase was related to the 2026 expanded marketing investment focused on awareness initiatives and increased commercial headcount, supporting the growth of PEDMARK. Consistent with prior commentary for 2026, we expect the fourth quarter of 2026 cash OPEX to be the lowest of the year.
At Fennec, we are focused on profitability as we grow the business, and as such, are presenting record non-GAAP adjusted EBITDA in the third quarter of 2026 of about $5.8 million, or 30% of net product sales, compared to $2 million in the comparable quarter a year ago, or 16% of net product sales, and up from $2.8 million in the second quarter, or 16% of net product sales. As stated previously, we have significant operating leverage in the business, with a predominantly fixed cost base. Our capital efficiency was evident this quarter, as our EBITDA grew by $3 million on a revenue growth of $2.3 million. Importantly, in the third quarter, we generated nearly $7 million in cash from operations, a record for Fennec. EPS. EPS in the third quarter was $0.12 per share, compared to a loss of $0.02 per share in the comparable quarter a year ago.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
